# A Long-term Extension Study of PCI-32765 (Ibrutinib)

Source: https://onco.cc/trials/nct01804686/  
OnCo record `nct01804686` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Ibrutinib in mantle cell lymphoma and follicular lymphoma, run by Janssen Research & Development, LLC, now recruiting.

## Summary

A Long-term Extension Study of PCI-32765 (Ibrutinib) is a phase 3 interventional study registered as NCT01804686 by Janssen Research & Development, LLC, with 700 participants planned, started 2013-09-09 and due to reach its primary completion in 2026-12-31. Interventions recorded: Ibrutinib. Conditions listed: Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Mantle Cell Lymphoma, Follicular Lymphoma. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT01804686
- Phase: 3
- Setting: PCI-32765CAN3001: A Phase 3b, Multicenter, Open-label, PCI-32765 (Ibrutinib) Long-term Extension Study
- Sponsor: Janssen Research & Development, LLC
- Enrolled: 700

## Sources

- ClinicalTrials.gov NCT01804686: https://clinicaltrials.gov/study/NCT01804686

## Connected records

- cancers: [Diffuse large B-cell lymphoma](https://onco.cc/cancers/dlbcl/), [Follicular lymphoma](https://onco.cc/cancers/follicular-lymphoma/), [Mantle cell lymphoma](https://onco.cc/cancers/mantle-cell-lymphoma/)
- drugs: [Ibrutinib](https://onco.cc/drugs/ibrutinib/)
- companies: [Johnson & Johnson](https://onco.cc/companies/johnson-johnson/)

---
JSON: https://onco.cc/api/v1/entities/nct01804686.json